0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Nonnarcotic Analgesics Market Research Report 2022
Published Date: October 2022
|
Report Code: QYRE-Auto-34H11928
Home | Market Reports | Health| Health Conditions| Pain Management
Global Nonnarcotic Analgesics Market Research Report 2022
BUY CHAPTERS

Global Nonnarcotic Analgesics Market Research Report 2022

Code: QYRE-Auto-34H11928
Report
October 2022
Pages:115
QYResearch
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
Nonnarcotic analgesics refer to non steroidal anti-inflammatory drugs that have nothing to do with or have little to do with central opioid receptors
Highlights

The global Nonnarcotic Analgesics market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.

North American market for Nonnarcotic Analgesics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

Asia-Pacific market for Nonnarcotic Analgesics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The major global manufacturers of Nonnarcotic Analgesics include GlaxoSmithKline Consumer Healthcare, Bayer Corporation, Atnahs Pharma, Baudax Bio, Prestige Brands, Inc., Cumberland Pharmaceuticals, Inc., Takeda Pharmaceutical Company, Pfizer Inc. and McNeil Consumer Healthcare, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.

The global market for Nonnarcotic Analgesics in Hospital is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Salicylates, which accounted for % of the global market of Nonnarcotic Analgesics in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Nonnarcotic Analgesics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nonnarcotic Analgesics.
The Nonnarcotic Analgesics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Nonnarcotic Analgesics market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nonnarcotic Analgesics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
GlaxoSmithKline Consumer Healthcare
Bayer Corporation
Atnahs Pharma
Baudax Bio
Prestige Brands, Inc.
Cumberland Pharmaceuticals, Inc.
Takeda Pharmaceutical Company
Pfizer Inc.
McNeil Consumer Healthcare
Eli Lilly and Company
Sun Pharmaceutical Industries
Validus Pharmaceuticals
Novartis Consumer Health
Pacira Pharmaceuticals, Inc.
Almatica Pharma
Actavis
Arbor Pharmaceuticals, LLC
PLx Pharma Inc.
Heron Therapeutics
Assertio Therapeutics, Inc.
Zyla Life Sciences
Jazz Pharmaceuticals plc
Product Type Insights
Global markets are presented by Nonnarcotic Analgesics type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Nonnarcotic Analgesics are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).

Nonnarcotic Analgesics segment by Type

Salicylates
Anilines
Pyrazolones
Other Organic Acids
Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Nonnarcotic Analgesics market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Nonnarcotic Analgesics market.

Nonnarcotic Analgesics segment by Application

Hospital
Pharmacy
Specialist Clinic
Other
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Nonnarcotic Analgesics market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nonnarcotic Analgesics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Nonnarcotic Analgesics and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Nonnarcotic Analgesics industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nonnarcotic Analgesics.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Nonnarcotic Analgesics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Nonnarcotic Analgesics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.
1 Nonnarcotic Analgesics Market Overview
1.1 Product Overview and Scope of Nonnarcotic Analgesics
1.2 Nonnarcotic Analgesics Segment by Type
1.2.1 Global Nonnarcotic Analgesics Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Salicylates
1.2.3 Anilines
1.2.4 Pyrazolones
1.2.5 Other Organic Acids
1.3 Nonnarcotic Analgesics Segment by Application
1.3.1 Global Nonnarcotic Analgesics Sales Comparison by Application: (2022-2028)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Specialist Clinic
1.3.5 Other
1.4 Global Nonnarcotic Analgesics Market Size Estimates and Forecasts
1.4.1 Global Nonnarcotic Analgesics Revenue 2017-2028
1.4.2 Global Nonnarcotic Analgesics Sales 2017-2028
1.4.3 Nonnarcotic Analgesics Market Size by Region: 2017 Versus 2021 Versus 2028
2 Nonnarcotic Analgesics Market Competition by Manufacturers
2.1 Global Nonnarcotic Analgesics Sales Market Share by Manufacturers (2017-2022)
2.2 Global Nonnarcotic Analgesics Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Nonnarcotic Analgesics Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Nonnarcotic Analgesics Manufacturing Sites, Area Served, Product Type
2.5 Nonnarcotic Analgesics Market Competitive Situation and Trends
2.5.1 Nonnarcotic Analgesics Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Nonnarcotic Analgesics Players Market Share by Revenue
2.5.3 Global Nonnarcotic Analgesics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Nonnarcotic Analgesics Retrospective Market Scenario by Region
3.1 Global Nonnarcotic Analgesics Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Nonnarcotic Analgesics Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Nonnarcotic Analgesics Market Facts & Figures by Country
3.3.1 North America Nonnarcotic Analgesics Sales by Country
3.3.2 North America Nonnarcotic Analgesics Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Nonnarcotic Analgesics Market Facts & Figures by Country
3.4.1 Europe Nonnarcotic Analgesics Sales by Country
3.4.2 Europe Nonnarcotic Analgesics Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Nonnarcotic Analgesics Market Facts & Figures by Region
3.5.1 Asia Pacific Nonnarcotic Analgesics Sales by Region
3.5.2 Asia Pacific Nonnarcotic Analgesics Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Nonnarcotic Analgesics Market Facts & Figures by Country
3.6.1 Latin America Nonnarcotic Analgesics Sales by Country
3.6.2 Latin America Nonnarcotic Analgesics Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Nonnarcotic Analgesics Market Facts & Figures by Country
3.7.1 Middle East and Africa Nonnarcotic Analgesics Sales by Country
3.7.2 Middle East and Africa Nonnarcotic Analgesics Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Nonnarcotic Analgesics Historic Market Analysis by Type
4.1 Global Nonnarcotic Analgesics Sales Market Share by Type (2017-2022)
4.2 Global Nonnarcotic Analgesics Revenue Market Share by Type (2017-2022)
4.3 Global Nonnarcotic Analgesics Price by Type (2017-2022)
5 Global Nonnarcotic Analgesics Historic Market Analysis by Application
5.1 Global Nonnarcotic Analgesics Sales Market Share by Application (2017-2022)
5.2 Global Nonnarcotic Analgesics Revenue Market Share by Application (2017-2022)
5.3 Global Nonnarcotic Analgesics Price by Application (2017-2022)
6 Key Companies Profiled
6.1 GlaxoSmithKline Consumer Healthcare
6.1.1 GlaxoSmithKline Consumer Healthcare Corporation Information
6.1.2 GlaxoSmithKline Consumer Healthcare Description and Business Overview
6.1.3 GlaxoSmithKline Consumer Healthcare Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.1.4 GlaxoSmithKline Consumer Healthcare Nonnarcotic Analgesics Product Portfolio
6.1.5 GlaxoSmithKline Consumer Healthcare Recent Developments/Updates
6.2 Bayer Corporation
6.2.1 Bayer Corporation Corporation Information
6.2.2 Bayer Corporation Description and Business Overview
6.2.3 Bayer Corporation Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Bayer Corporation Nonnarcotic Analgesics Product Portfolio
6.2.5 Bayer Corporation Recent Developments/Updates
6.3 Atnahs Pharma
6.3.1 Atnahs Pharma Corporation Information
6.3.2 Atnahs Pharma Description and Business Overview
6.3.3 Atnahs Pharma Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Atnahs Pharma Nonnarcotic Analgesics Product Portfolio
6.3.5 Atnahs Pharma Recent Developments/Updates
6.4 Baudax Bio
6.4.1 Baudax Bio Corporation Information
6.4.2 Baudax Bio Description and Business Overview
6.4.3 Baudax Bio Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Baudax Bio Nonnarcotic Analgesics Product Portfolio
6.4.5 Baudax Bio Recent Developments/Updates
6.5 Prestige Brands, Inc.
6.5.1 Prestige Brands, Inc. Corporation Information
6.5.2 Prestige Brands, Inc. Description and Business Overview
6.5.3 Prestige Brands, Inc. Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Prestige Brands, Inc. Nonnarcotic Analgesics Product Portfolio
6.5.5 Prestige Brands, Inc. Recent Developments/Updates
6.6 Cumberland Pharmaceuticals, Inc.
6.6.1 Cumberland Pharmaceuticals, Inc. Corporation Information
6.6.2 Cumberland Pharmaceuticals, Inc. Description and Business Overview
6.6.3 Cumberland Pharmaceuticals, Inc. Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Cumberland Pharmaceuticals, Inc. Nonnarcotic Analgesics Product Portfolio
6.6.5 Cumberland Pharmaceuticals, Inc. Recent Developments/Updates
6.7 Takeda Pharmaceutical Company
6.6.1 Takeda Pharmaceutical Company Corporation Information
6.6.2 Takeda Pharmaceutical Company Description and Business Overview
6.6.3 Takeda Pharmaceutical Company Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Takeda Pharmaceutical Company Nonnarcotic Analgesics Product Portfolio
6.7.5 Takeda Pharmaceutical Company Recent Developments/Updates
6.8 Pfizer Inc.
6.8.1 Pfizer Inc. Corporation Information
6.8.2 Pfizer Inc. Description and Business Overview
6.8.3 Pfizer Inc. Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Pfizer Inc. Nonnarcotic Analgesics Product Portfolio
6.8.5 Pfizer Inc. Recent Developments/Updates
6.9 McNeil Consumer Healthcare
6.9.1 McNeil Consumer Healthcare Corporation Information
6.9.2 McNeil Consumer Healthcare Description and Business Overview
6.9.3 McNeil Consumer Healthcare Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.9.4 McNeil Consumer Healthcare Nonnarcotic Analgesics Product Portfolio
6.9.5 McNeil Consumer Healthcare Recent Developments/Updates
6.10 Eli Lilly and Company
6.10.1 Eli Lilly and Company Corporation Information
6.10.2 Eli Lilly and Company Description and Business Overview
6.10.3 Eli Lilly and Company Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Eli Lilly and Company Nonnarcotic Analgesics Product Portfolio
6.10.5 Eli Lilly and Company Recent Developments/Updates
6.11 Sun Pharmaceutical Industries
6.11.1 Sun Pharmaceutical Industries Corporation Information
6.11.2 Sun Pharmaceutical Industries Nonnarcotic Analgesics Description and Business Overview
6.11.3 Sun Pharmaceutical Industries Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Sun Pharmaceutical Industries Nonnarcotic Analgesics Product Portfolio
6.11.5 Sun Pharmaceutical Industries Recent Developments/Updates
6.12 Validus Pharmaceuticals
6.12.1 Validus Pharmaceuticals Corporation Information
6.12.2 Validus Pharmaceuticals Nonnarcotic Analgesics Description and Business Overview
6.12.3 Validus Pharmaceuticals Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Validus Pharmaceuticals Nonnarcotic Analgesics Product Portfolio
6.12.5 Validus Pharmaceuticals Recent Developments/Updates
6.13 Novartis Consumer Health
6.13.1 Novartis Consumer Health Corporation Information
6.13.2 Novartis Consumer Health Nonnarcotic Analgesics Description and Business Overview
6.13.3 Novartis Consumer Health Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Novartis Consumer Health Nonnarcotic Analgesics Product Portfolio
6.13.5 Novartis Consumer Health Recent Developments/Updates
6.14 Pacira Pharmaceuticals, Inc.
6.14.1 Pacira Pharmaceuticals, Inc. Corporation Information
6.14.2 Pacira Pharmaceuticals, Inc. Nonnarcotic Analgesics Description and Business Overview
6.14.3 Pacira Pharmaceuticals, Inc. Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Pacira Pharmaceuticals, Inc. Nonnarcotic Analgesics Product Portfolio
6.14.5 Pacira Pharmaceuticals, Inc. Recent Developments/Updates
6.15 Almatica Pharma
6.15.1 Almatica Pharma Corporation Information
6.15.2 Almatica Pharma Nonnarcotic Analgesics Description and Business Overview
6.15.3 Almatica Pharma Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Almatica Pharma Nonnarcotic Analgesics Product Portfolio
6.15.5 Almatica Pharma Recent Developments/Updates
6.16 Actavis
6.16.1 Actavis Corporation Information
6.16.2 Actavis Nonnarcotic Analgesics Description and Business Overview
6.16.3 Actavis Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Actavis Nonnarcotic Analgesics Product Portfolio
6.16.5 Actavis Recent Developments/Updates
6.17 Arbor Pharmaceuticals, LLC
6.17.1 Arbor Pharmaceuticals, LLC Corporation Information
6.17.2 Arbor Pharmaceuticals, LLC Nonnarcotic Analgesics Description and Business Overview
6.17.3 Arbor Pharmaceuticals, LLC Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Arbor Pharmaceuticals, LLC Nonnarcotic Analgesics Product Portfolio
6.17.5 Arbor Pharmaceuticals, LLC Recent Developments/Updates
6.18 PLx Pharma Inc.
6.18.1 PLx Pharma Inc. Corporation Information
6.18.2 PLx Pharma Inc. Nonnarcotic Analgesics Description and Business Overview
6.18.3 PLx Pharma Inc. Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.18.4 PLx Pharma Inc. Nonnarcotic Analgesics Product Portfolio
6.18.5 PLx Pharma Inc. Recent Developments/Updates
6.19 Heron Therapeutics
6.19.1 Heron Therapeutics Corporation Information
6.19.2 Heron Therapeutics Nonnarcotic Analgesics Description and Business Overview
6.19.3 Heron Therapeutics Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Heron Therapeutics Nonnarcotic Analgesics Product Portfolio
6.19.5 Heron Therapeutics Recent Developments/Updates
6.20 Assertio Therapeutics, Inc.
6.20.1 Assertio Therapeutics, Inc. Corporation Information
6.20.2 Assertio Therapeutics, Inc. Nonnarcotic Analgesics Description and Business Overview
6.20.3 Assertio Therapeutics, Inc. Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.20.4 Assertio Therapeutics, Inc. Nonnarcotic Analgesics Product Portfolio
6.20.5 Assertio Therapeutics, Inc. Recent Developments/Updates
6.21 Zyla Life Sciences
6.21.1 Zyla Life Sciences Corporation Information
6.21.2 Zyla Life Sciences Nonnarcotic Analgesics Description and Business Overview
6.21.3 Zyla Life Sciences Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.21.4 Zyla Life Sciences Nonnarcotic Analgesics Product Portfolio
6.21.5 Zyla Life Sciences Recent Developments/Updates
6.22 Jazz Pharmaceuticals plc
6.22.1 Jazz Pharmaceuticals plc Corporation Information
6.22.2 Jazz Pharmaceuticals plc Nonnarcotic Analgesics Description and Business Overview
6.22.3 Jazz Pharmaceuticals plc Nonnarcotic Analgesics Sales, Revenue and Gross Margin (2017-2022)
6.22.4 Jazz Pharmaceuticals plc Nonnarcotic Analgesics Product Portfolio
6.22.5 Jazz Pharmaceuticals plc Recent Developments/Updates
7 Nonnarcotic Analgesics Manufacturing Cost Analysis
7.1 Nonnarcotic Analgesics Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Nonnarcotic Analgesics
7.4 Nonnarcotic Analgesics Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Nonnarcotic Analgesics Distributors List
8.3 Nonnarcotic Analgesics Customers
9 Nonnarcotic Analgesics Market Dynamics
9.1 Nonnarcotic Analgesics Industry Trends
9.2 Nonnarcotic Analgesics Market Drivers
9.3 Nonnarcotic Analgesics Market Challenges
9.4 Nonnarcotic Analgesics Market Restraints
10 Global Market Forecast
10.1 Nonnarcotic Analgesics Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Nonnarcotic Analgesics by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Nonnarcotic Analgesics by Type (2023-2028)
10.2 Nonnarcotic Analgesics Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Nonnarcotic Analgesics by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Nonnarcotic Analgesics by Application (2023-2028)
10.3 Nonnarcotic Analgesics Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Nonnarcotic Analgesics by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Nonnarcotic Analgesics by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
    Table 1. Global Nonnarcotic Analgesics Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
    Table 2. Global Nonnarcotic Analgesics Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
    Table 3. Global Nonnarcotic Analgesics Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
    Table 4. Global Nonnarcotic Analgesics Market Competitive Situation by Manufacturers in 2021
    Table 5. Global Nonnarcotic Analgesics Sales (K Units) of Key Manufacturers (2017-2022)
    Table 6. Global Nonnarcotic Analgesics Sales Market Share by Manufacturers (2017-2022)
    Table 7. Global Nonnarcotic Analgesics Revenue (US$ Million) by Manufacturers (2017-2022)
    Table 8. Global Nonnarcotic Analgesics Revenue Share by Manufacturers (2017-2022)
    Table 9. Global Market Nonnarcotic Analgesics Average Price (US$/Unit) of Key Manufacturers (2017-2022)
    Table 10. Manufacturers Nonnarcotic Analgesics Manufacturing Sites and Area Served
    Table 11. Manufacturers Nonnarcotic Analgesics Product Type
    Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Nonnarcotic Analgesics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nonnarcotic Analgesics as of 2021)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Global Nonnarcotic Analgesics Sales by Region (2017-2022) & (K Units)
    Table 16. Global Nonnarcotic Analgesics Sales Market Share by Region (2017-2022)
    Table 17. Global Nonnarcotic Analgesics Revenue by Region (2017-2022) & (US$ Million)
    Table 18. Global Nonnarcotic Analgesics Revenue Market Share by Region (2017-2022)
    Table 19. North America Nonnarcotic Analgesics Sales by Country (2017-2022) & (K Units)
    Table 20. North America Nonnarcotic Analgesics Sales Market Share by Country (2017-2022)
    Table 21. North America Nonnarcotic Analgesics Revenue by Country (2017-2022) & (US$ Million)
    Table 22. North America Nonnarcotic Analgesics Revenue Market Share by Country (2017-2022)
    Table 23. Europe Nonnarcotic Analgesics Sales by Country (2017-2022) & (K Units)
    Table 24. Europe Nonnarcotic Analgesics Sales Market Share by Country (2017-2022)
    Table 25. Europe Nonnarcotic Analgesics Revenue by Country (2017-2022) & (US$ Million)
    Table 26. Europe Nonnarcotic Analgesics Revenue Market Share by Country (2017-2022)
    Table 27. Asia Pacific Nonnarcotic Analgesics Sales by Region (2017-2022) & (K Units)
    Table 28. Asia Pacific Nonnarcotic Analgesics Sales Market Share by Region (2017-2022)
    Table 29. Asia Pacific Nonnarcotic Analgesics Revenue by Region (2017-2022) & (US$ Million)
    Table 30. Asia Pacific Nonnarcotic Analgesics Revenue Market Share by Region (2017-2022)
    Table 31. Latin America Nonnarcotic Analgesics Sales by Country (2017-2022) & (K Units)
    Table 32. Latin America Nonnarcotic Analgesics Sales Market Share by Country (2017-2022)
    Table 33. Latin America Nonnarcotic Analgesics Revenue by Country (2017-2022) & (US$ Million)
    Table 34. Latin America Nonnarcotic Analgesics Revenue Market Share by Country (2017-2022)
    Table 35. Middle East and Africa Nonnarcotic Analgesics Sales by Country (2017-2022) & (K Units)
    Table 36. Middle East and Africa Nonnarcotic Analgesics Sales Market Share by Country (2017-2022)
    Table 37. Middle East and Africa Nonnarcotic Analgesics Revenue by Country (2017-2022) & (US$ Million)
    Table 38. Middle East and Africa Nonnarcotic Analgesics Revenue Market Share by Country (2017-2022)
    Table 39. Global Nonnarcotic Analgesics Sales by Type (2017-2022) & (K Units)
    Table 40. Global Nonnarcotic Analgesics Sales Market Share by Type (2017-2022)
    Table 41. Global Nonnarcotic Analgesics Revenue by Type (2017-2022) & (US$ Million)
    Table 42. Global Nonnarcotic Analgesics Revenue Share by Type (2017-2022)
    Table 43. Global Nonnarcotic Analgesics Price by Type (2017-2022) & (US$/Unit)
    Table 44. Global Nonnarcotic Analgesics Sales (K Units) by Application (2017-2022)
    Table 45. Global Nonnarcotic Analgesics Sales Market Share by Application (2017-2022)
    Table 46. Global Nonnarcotic Analgesics Revenue by Application (2017-2022) & (US$ Million)
    Table 47. Global Nonnarcotic Analgesics Revenue Share by Application (2017-2022)
    Table 48. Global Nonnarcotic Analgesics Price by Application (2017-2022) & (US$/Unit)
    Table 49. GlaxoSmithKline Consumer Healthcare Corporation Information
    Table 50. GlaxoSmithKline Consumer Healthcare Description and Business Overview
    Table 51. GlaxoSmithKline Consumer Healthcare Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 52. GlaxoSmithKline Consumer Healthcare Nonnarcotic Analgesics Product
    Table 53. GlaxoSmithKline Consumer Healthcare Recent Developments/Updates
    Table 54. Bayer Corporation Corporation Information
    Table 55. Bayer Corporation Description and Business Overview
    Table 56. Bayer Corporation Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 57. Bayer Corporation Nonnarcotic Analgesics Product
    Table 58. Bayer Corporation Recent Developments/Updates
    Table 59. Atnahs Pharma Corporation Information
    Table 60. Atnahs Pharma Description and Business Overview
    Table 61. Atnahs Pharma Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 62. Atnahs Pharma Nonnarcotic Analgesics Product
    Table 63. Atnahs Pharma Recent Developments/Updates
    Table 64. Baudax Bio Corporation Information
    Table 65. Baudax Bio Description and Business Overview
    Table 66. Baudax Bio Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 67. Baudax Bio Nonnarcotic Analgesics Product
    Table 68. Baudax Bio Recent Developments/Updates
    Table 69. Prestige Brands, Inc. Corporation Information
    Table 70. Prestige Brands, Inc. Description and Business Overview
    Table 71. Prestige Brands, Inc. Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 72. Prestige Brands, Inc. Nonnarcotic Analgesics Product
    Table 73. Prestige Brands, Inc. Recent Developments/Updates
    Table 74. Cumberland Pharmaceuticals, Inc. Corporation Information
    Table 75. Cumberland Pharmaceuticals, Inc. Description and Business Overview
    Table 76. Cumberland Pharmaceuticals, Inc. Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 77. Cumberland Pharmaceuticals, Inc. Nonnarcotic Analgesics Product
    Table 78. Cumberland Pharmaceuticals, Inc. Recent Developments/Updates
    Table 79. Takeda Pharmaceutical Company Corporation Information
    Table 80. Takeda Pharmaceutical Company Description and Business Overview
    Table 81. Takeda Pharmaceutical Company Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 82. Takeda Pharmaceutical Company Nonnarcotic Analgesics Product
    Table 83. Takeda Pharmaceutical Company Recent Developments/Updates
    Table 84. Pfizer Inc. Corporation Information
    Table 85. Pfizer Inc. Description and Business Overview
    Table 86. Pfizer Inc. Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 87. Pfizer Inc. Nonnarcotic Analgesics Product
    Table 88. Pfizer Inc. Recent Developments/Updates
    Table 89. McNeil Consumer Healthcare Corporation Information
    Table 90. McNeil Consumer Healthcare Description and Business Overview
    Table 91. McNeil Consumer Healthcare Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 92. McNeil Consumer Healthcare Nonnarcotic Analgesics Product
    Table 93. McNeil Consumer Healthcare Recent Developments/Updates
    Table 94. Eli Lilly and Company Corporation Information
    Table 95. Eli Lilly and Company Description and Business Overview
    Table 96. Eli Lilly and Company Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 97. Eli Lilly and Company Nonnarcotic Analgesics Product
    Table 98. Eli Lilly and Company Recent Developments/Updates
    Table 99. Sun Pharmaceutical Industries Corporation Information
    Table 100. Sun Pharmaceutical Industries Description and Business Overview
    Table 101. Sun Pharmaceutical Industries Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 102. Sun Pharmaceutical Industries Nonnarcotic Analgesics Product
    Table 103. Sun Pharmaceutical Industries Recent Developments/Updates
    Table 104. Validus Pharmaceuticals Corporation Information
    Table 105. Validus Pharmaceuticals Description and Business Overview
    Table 106. Validus Pharmaceuticals Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 107. Validus Pharmaceuticals Nonnarcotic Analgesics Product
    Table 108. Validus Pharmaceuticals Recent Developments/Updates
    Table 109. Novartis Consumer Health Corporation Information
    Table 110. Novartis Consumer Health Description and Business Overview
    Table 111. Novartis Consumer Health Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 112. Novartis Consumer Health Nonnarcotic Analgesics Product
    Table 113. Novartis Consumer Health Recent Developments/Updates
    Table 114. Pacira Pharmaceuticals, Inc. Corporation Information
    Table 115. Pacira Pharmaceuticals, Inc. Description and Business Overview
    Table 116. Pacira Pharmaceuticals, Inc. Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 117. Pacira Pharmaceuticals, Inc. Nonnarcotic Analgesics Product
    Table 118. Pacira Pharmaceuticals, Inc. Recent Developments/Updates
    Table 119. Almatica Pharma Corporation Information
    Table 120. Almatica Pharma Description and Business Overview
    Table 121. Almatica Pharma Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 122. Almatica Pharma Nonnarcotic Analgesics Product
    Table 123. Almatica Pharma Recent Developments/Updates
    Table 124. Actavis Corporation Information
    Table 125. Actavis Description and Business Overview
    Table 126. Actavis Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 127. Actavis Nonnarcotic Analgesics Product
    Table 128. Actavis Recent Developments/Updates
    Table 129. Arbor Pharmaceuticals, LLC Corporation Information
    Table 130. Arbor Pharmaceuticals, LLC Description and Business Overview
    Table 131. Arbor Pharmaceuticals, LLC Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 132. Arbor Pharmaceuticals, LLC Nonnarcotic Analgesics Product
    Table 133. Arbor Pharmaceuticals, LLC Recent Developments/Updates
    Table 134. PLx Pharma Inc. Corporation Information
    Table 135. PLx Pharma Inc. Description and Business Overview
    Table 136. PLx Pharma Inc. Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 137. PLx Pharma Inc. Nonnarcotic Analgesics Product
    Table 138. PLx Pharma Inc. Recent Developments/Updates
    Table 139. Heron Therapeutics Corporation Information
    Table 140. Heron Therapeutics Description and Business Overview
    Table 141. Heron Therapeutics Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 142. Heron Therapeutics Nonnarcotic Analgesics Product
    Table 143. Heron Therapeutics Recent Developments/Updates
    Table 144. Assertio Therapeutics, Inc. Corporation Information
    Table 145. Assertio Therapeutics, Inc. Description and Business Overview
    Table 146. Assertio Therapeutics, Inc. Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 147. Assertio Therapeutics, Inc. Nonnarcotic Analgesics Product
    Table 148. Assertio Therapeutics, Inc. Recent Developments/Updates
    Table 149. Zyla Life Sciences Corporation Information
    Table 150. Zyla Life Sciences Description and Business Overview
    Table 151. Zyla Life Sciences Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 152. Zyla Life Sciences Nonnarcotic Analgesics Product
    Table 153. Zyla Life Sciences Recent Developments/Updates
    Table 154. Jazz Pharmaceuticals plc Corporation Information
    Table 155. Jazz Pharmaceuticals plc Description and Business Overview
    Table 156. Jazz Pharmaceuticals plc Nonnarcotic Analgesics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 157. Jazz Pharmaceuticals plc Nonnarcotic Analgesics Product
    Table 158. Jazz Pharmaceuticals plc Recent Developments/Updates
    Table 159. Production Base and Market Concentration Rate of Raw Material
    Table 160. Key Suppliers of Raw Materials
    Table 161. Nonnarcotic Analgesics Distributors List
    Table 162. Nonnarcotic Analgesics Customers List
    Table 163. Nonnarcotic Analgesics Market Trends
    Table 164. Nonnarcotic Analgesics Market Drivers
    Table 165. Nonnarcotic Analgesics Market Challenges
    Table 166. Nonnarcotic Analgesics Market Restraints
    Table 167. Global Nonnarcotic Analgesics Sales Forecast by Type (2023-2028) & (K Units)
    Table 168. Global Nonnarcotic Analgesics Sales Market Share Forecast by Type (2023-2028)
    Table 169. Global Nonnarcotic Analgesics Revenue Forecast by Type (2023-2028) & (US$ Million)
    Table 170. Global Nonnarcotic Analgesics Revenue Market Share Forecast by Type (2023-2028)
    Table 171. Global Nonnarcotic Analgesics Sales Forecast by Application (2023-2028) & (K Units)
    Table 172. Global Nonnarcotic Analgesics Sales Market Share Forecast by Application (2023-2028)
    Table 173. Global Nonnarcotic Analgesics Revenue Forecast by Application (2023-2028) & (US$ Million)
    Table 174. Global Nonnarcotic Analgesics Revenue Market Share Forecast by Application (2023-2028)
    Table 175. Global Nonnarcotic Analgesics Sales Forecast by Region (2023-2028) & (K Units)
    Table 176. Global Nonnarcotic Analgesics Sales Market Share Forecast by Region (2023-2028)
    Table 177. Global Nonnarcotic Analgesics Revenue Forecast by Region (2023-2028) & (US$ Million)
    Table 178. Global Nonnarcotic Analgesics Revenue Market Share Forecast by Region (2023-2028)
    Table 179. Research Programs/Design for This Report
    Table 180. Key Data Information from Secondary Sources
    Table 181. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Nonnarcotic Analgesics
    Figure 2. Global Nonnarcotic Analgesics Market Share by Type in 2021 & 2028
    Figure 3. Salicylates Product Picture
    Figure 4. Anilines Product Picture
    Figure 5. Pyrazolones Product Picture
    Figure 6. Other Organic Acids Product Picture
    Figure 7. Global Nonnarcotic Analgesics Market Share by Application in 2021 & 2028
    Figure 8. Hospital
    Figure 9. Pharmacy
    Figure 10. Specialist Clinic
    Figure 11. Other
    Figure 12. Global Nonnarcotic Analgesics Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Nonnarcotic Analgesics Market Size (2017-2028) & (US$ Million)
    Figure 14. Global Nonnarcotic Analgesics Sales (2017-2028) & (K Units)
    Figure 15. Nonnarcotic Analgesics Sales Share by Manufacturers in 2021
    Figure 16. Global Nonnarcotic Analgesics Revenue Share by Manufacturers in 2021
    Figure 17. The Global 5 and 10 Largest Nonnarcotic Analgesics Players: Market Share by Revenue in 2021
    Figure 18. Nonnarcotic Analgesics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
    Figure 19. Global Nonnarcotic Analgesics Sales Market Share by Region (2017-2022)
    Figure 20. Global Nonnarcotic Analgesics Sales Market Share by Region in 2021
    Figure 21. Global Nonnarcotic Analgesics Revenue Market Share by Region (2017-2022)
    Figure 22. Global Nonnarcotic Analgesics Revenue Market Share by Region in 2021
    Figure 23. United States Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 24. Canada Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 25. Germany Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 26. France Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 27. U.K. Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 28. Italy Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 29. Russia Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 30. China Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 31. Japan Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 32. South Korea Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 33. India Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 34. Australia Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 35. China Taiwan Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 36. Indonesia Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 37. Thailand Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 38. Malaysia Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 39. Mexico Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 40. Brazil Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 41. Argentina Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 42. Colombia Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 43. Turkey Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 44. Saudi Arabia Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 45. UAE Nonnarcotic Analgesics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 46. Sales Market Share of Nonnarcotic Analgesics by Type (2017-2022)
    Figure 47. Manufacturing Cost Structure of Nonnarcotic Analgesics
    Figure 48. Manufacturing Process Analysis of Nonnarcotic Analgesics
    Figure 49. Nonnarcotic Analgesics Industrial Chain Analysis
    Figure 50. Channels of Distribution
    Figure 51. Distributors Profiles
    Figure 52. Bottom-up and Top-down Approaches for This Report
    Figure 53. Data Triangulation
    Figure 54. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS